Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Danish Medicines Agency, the most common co-covered peer. Each story carries 3 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Aug 1, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Danish Medicines Agency, the most common co-covered peer. Each story carries 3 original sources on average, compared with 2.5 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 5.7 for that window. We currently track 1 Biotech story that mention Meningioma, all published on August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Meningioma. Shared-story counts are live from our verified record — not editorial picks.
The Danish Medicines Agency’s real-world evidence analysis implicates drospirenone, desogestrel, gestodene, and others in meningioma development, reshaping the risk-benefit landscape for pharmaceutical manufacturers and future contraceptive R&D.
Source: 965therock.com · koolfmabilene.com
Meningioma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
